Human induced pluripotent stem cells (iPSCs) offer a promising and unlimited source of cells for curative cell replacement therapies in the treatment of devastating diseases such as Parkinson’s disease (PD) and diabetes.
However, in order to commercialize these therapies to treat a large number of individuals at affordable costs, it is necessary to demonstrate the safety and efficacy of these therapies and industrialize the manufacturing process for iPSC-derived functional cells in a scalable and controlled manner.
This webinar provides a checklist of the major steps we have taken at Lonza towards the industrialization of iPSC-derived cell therapy products with focus on the development of a current Good Manufacturing Practice (cGMP)-compliant iPSC manufacturing process, characterization of iPSCs, development of scalable, computer-controlled bioprocessing system for expansion and / or directed differentiation of human iPSC using microcarrier-based and carrier-free strategies.
Key learning points include:
The Lonza logo is a Lonza Ltd. Trademark